(CIX: WRAL30)  1,132.70  up arrow+0.08  (0.01 %)  Updated: 08:10 PM EST, Nov 21 2014
(NQ: Apple)  116.47  up arrow+0.16  (0.14 %)  Updated: 08:10 PM EST, Nov 21 2014
(NY: QUINTILES)  57.86  up arrow+0.11  (0.19 %)  Updated: 06:40 PM EST, Nov 21 2014
(OP: BASF SE)  91.10  up arrow+1.95  (2.19 %)  Updated: 05:20 PM EST, Nov 21 2014
(NQ: BioCryst)  10.33  down arrow-0.02  (-0.19 %)  Updated: 08:10 PM EST, Nov 21 2014
(NQ: BioDelivery)  14.29  down arrow-0.17  (-1.18 %)  Updated: 08:10 PM EST, Nov 21 2014
(NQ: CEMP)  13.63  up arrow+0.2  (1.49 %)  Updated: 08:10 PM EST, Nov 21 2014
(NQ: Cisco Systems)  26.88  up arrow+0.07  (0.26 %)  Updated: 08:10 PM EST, Nov 21 2014
(NQ: Cree)  35.51  up arrow+0.71  (2.04 %)  Updated: 08:10 PM EST, Nov 21 2014
(NQ: DARA)  0.81  up arrow+0.06  (7.93 %)  Updated: 08:10 PM EST, Nov 21 2014
(NY: EMC CORPORATION)  29.90  up arrow+0.04  (0.13 %)  Updated: 06:40 PM EST, Nov 21 2014
(NQ: Extreme Networks)  3.68  down arrow-0.14  (-3.66 %)  Updated: 08:10 PM EST, Nov 21 2014
(NQ: FB)  73.75  up arrow+0.15  (0.2 %)  Updated: 08:10 PM EST, Nov 21 2014
(NY: GLAXOSMITHKLINE)  46.40  up arrow+0.02  (0.04 %)  Updated: 06:40 PM EST, Nov 21 2014
(NQ: GOOG)  537.50  up arrow+2.67  (0.5 %)  Updated: 08:10 PM EST, Nov 21 2014
(NY: IBM)  160.92  up arrow+0.28  (0.17 %)  Updated: 06:40 PM EST, Nov 21 2014
(NY: LH)  100.46  down arrow-0.18  (-0.18 %)  Updated: 06:40 PM EST, Nov 21 2014
(OP: Lenovo Group)  27.55  up arrow+0.9  (3.38 %)  Updated: 05:20 PM EST, Nov 21 2014
(NY: MRK)  59.66  up arrow+0.28  (0.47 %)  Updated: 06:40 PM EST, Nov 21 2014
(NQ: Microsoft Corp)  47.98  down arrow-0.72  (-1.48 %)  Updated: 08:10 PM EST, Nov 21 2014
(NQ: NTAP)  42.31  up arrow+0.11  (0.26 %)  Updated: 08:10 PM EST, Nov 21 2014
(NY: NOVARTIS AG)  94.98  down arrow-0.29  (-0.3 %)  Updated: 06:40 PM EST, Nov 21 2014
(OP: Novozymes A/S)  45.82  down arrow-0.6  (-1.29 %)  Updated: 05:20 PM EST, Nov 21 2014
(NY: PFIZER)  30.45  up arrow+0.01  (0.03 %)  Updated: 06:40 PM EST, Nov 21 2014
(NQ: Pozen)  8.86  down arrow-0.07  (-0.78 %)  Updated: 08:10 PM EST, Nov 21 2014
(NY: RED HAT)  62.25  down arrow-0.54  (-0.86 %)  Updated: 06:40 PM EST, Nov 21 2014
(NQ: BBRY)  10.24  up arrow+0.19  (1.89 %)  Updated: 08:10 PM EST, Nov 21 2014
(NQ: Salix)  102.90  up arrow+2.47  (2.46 %)  Updated: 08:10 PM EST, Nov 21 2014
(NQ: SQI)  14.91  down arrow-0.01  (-0.07 %)  Updated: 08:10 PM EST, Nov 21 2014

Posts tagged “GSK”

November 19

Survey shows corporate progress in embracing LGBT equality

A new survey from the Human Rights Campaign finds that a record number of companies, including seven in North Carolina, received perfect scores in corporate inclusion for lesbian, gay, bisexual and transgender employees. Bank of America, Blue Cross Blue Shield of NC and GlaxoSmithKline are among those receiving a "100" on the Corporate Equality Index.

Survey finds more LGBT equality in corporate America Survey finds more LGBT equality in corporate America

November 18

Uber regulation coming in NC?; IBM's $1.25B outsourcing deal; GSK Ebola vaccine update; FTC says TRUSTe deceived consumers; SAP to pay Oracle $359M

Bulldog In today's Bulldog wrapup of tech and life science news: A N.C. General Assembly committee is to discuss possible Uber regulations; IBM lands a $1.25 billion outsourcing deal with Lufthansa; GSK's Ebola vaccine is safe in early tests; the FTC settles complaint with TRUSTe; and SAP will pay Oracle $359 million to settle a long legal battle.

October 31

Longtime GSK exec Viehbacher ousted as Sanofi CEO

Chris Viehbacher Chris Viehbacher, a longtime GSK executive and triangle resident who lost out in the battle to become CEO of that job giant, has lost his job as CEO at French drugmaker Sanofi.

Updated October 24

Premium Lock GSK exec on Ebola vaccine trial: 'We only have one shot to get this right'

Ebola The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. And GSK is ramping up vaccine trial. Paul Allen chips in $100 million. But will all this be enough to stop Ebola?

October 22

Premium Lock Witty defends himself, GSK: 'Look at what we're able to achive'

Having been fined nearly $500 million in China for bribery, facing investigations in other countries and battling lagging revenue, GSK now faces more cost cuts and is contemplating a stock offering for its ViiV Healthcare. But GSK's CEO Andrew Witty defended himself and his strategy in discussing the drug giant's most recent quarterly earnings report on Wednesday. "Look at what we're able to achieve," he says.

GSK's Andrew Witty talks strategy GSK's Andrew Witty talks strategy

October 21

Premium Lock GSK's Ebola vaccine could be tested in January, WHO says

Ebola Tens of thousands of doses of experimental Ebola vaccines -including one from GlaxoSmithKline - could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday.

Updated October 17

Premium Lock Exec: GSK's Ebola vaccine will 'come too late' for current epidemic

Ebola The head of Ebola vaccine research at GlaxoSmithKline tells the BBC that the company's treatment that is now being tested isn't likely to be "the primary answer to this particular outbreak." He concedes GSK could have moved faster.

Updated October 8

Premium Lock Lenovo class-action suit; new GSK probe; AT&T data breach; Salix drug wins OK; Facebook's anonymous app; Lenovo-NEC deal

Bulldog In today's Bulldog blog wrapping up the latest technology and life science news: Lenovo settles a class-action suit over Wi-Fi; GSK faces another bribery investigation; AT&T data breach; FDA OKs Salix colitis treatment; Facebook is developing an app for anonymous posts; and Lenovo extends its partnership with NEC.

September 30

Premium Lock GSK pledges $5M for startups; UNC, Duke scientists land grants for BRAIN Initiative

President Obama's BRAIN Initiative - Brain Research through Advancing Innovative Neurotechnologies - second year kickoff includes three RTP connections: Funding from GlaxoSmithKline and research grants for teams at UNC-Chapel Hill as well as Duke.

An NIH look at the brain  An NIH look at the brain

September 25

Premium Lock GSK confirms bank exec to take over as board chairman

GSK  Drug giant GlaxoSmithKline will have a new chairman a year from now: Philip Hampton, the current chair at Royal Bank of Scotland Group. Hampton will first join the GSK board as of Jan. 1 as a director.

Updated September 25

Premium Lock New GSK chairman; Lenovo stock pressure; FTC bitcoin crackdown; FAA to OK drones; Cree's new competition

Bulldog In today's wrapup of life science and technology news: GSK is getting a new chairman in wake of the China bribery scandal, says The Times of London; Lenovo stock faces price pressure; FTC takes aim at bitcoins; FAA to OK drones for Hollywood; Cree's new competition from Philips.

Updated September 19

Premium Lock GSK China exec convicted, drug giant fined $492M in bribery scandal

GSK in China  A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been sentenced to prison in a bribery case but may never have to serve that time. GSK also issued an apology.

September 19

Premium Lock 'GSK sincerely apologizes' in statement after scandal verdict

Through its GSK China website, the drug giant formally apologized to the Chinese government and people for "illegal activities" that led to a $492 million fine and conviction of its top executive in that country. The full statement follows.

GSK's apology on front page of its China website GSK's apology on front page of its China website

August 29

Premium Lock US to begin tests of GSK's Ebola vaccine next week

The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. Beginning Tuesday, it will test 20 healthy adult volunteers to see if the virus is safe and triggers an adequate response in their immune systems.

Ebola virus     Ebola virus

Updated August 28

Premium Lock US to test GSK's vaccine for Ebola; Greenville lab could produce a treatment

A possible vaccine to treat the spreading Ebola outbreak in Africa could be coming from GSK. Plus, a lab in Greenville could be a site where a treatment is produced.

Ebola virus     Ebola virus

Updated August 14

Premium Lock Duke doctor warns against use of untested Ebola drugs

As more companies step up efforts to develop vaccines targeting ebola and the disease outbreak spreads in Africa, a doctor at Duke University warns that using untested drugs "could prove disastrous."

Updated August 12

Premium Lock Wall Street Journal report questions investor confidence in GSK's CEO

Another day, another headache in the global press for GlaxoSmithKline and its CEO Andrew Witty. This time it's an in-depth report in The Wall Street Journal in which some investors question Witty's performance as the drug giant fights lagging sales and scandal.

Updated August 11

Premium Lock GSK could have first ebola vaccine in 2015, world health official says

A World Health Organization official says the first ebola vaccine could be available in 2015. It's being developed by GlaxoSmithKline. However, the drug giant says "it's too early" to speculate on timing.

Ebola fight   Ebola fight

August 11

Premium Lock GSK-hired investigators face jail time; son blames Glaxo

China business    "The root of the problem really from where I'm sitting is the way GSK behaved in this matter," the son of convicted investigator tells London-based broadcaster Sky News. GSK has said it hired the couple to investigate a security breach but not bribery allegations.

Tags: GSK
August 8

Premium Lock Trial of British-US couple with Glaxo ties continues in China

China business    Peter Humphrey and Yingzeng Yu worked under contract for British pharmaceutical giant GlaxoSmithKline, which is accused in a separate case of bribing Chinese doctors and hospitals to use its products. Authorities have not indicated whether these two cases are linked as the fraud trial continues in China.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith


Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa